Green light for new €3bn Innovative Medicines Initiative
This article was originally published in Scrip
Executive Summary
The European Parliament has voted in favor of the second Innovative Medicines Initiative (IMI2), a €3bn public-private research partnership run jointly by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is aimed at improving the process of drug development by supporting cooperation in R&D.